FDA Approves Component of Chemotherapy Regimen for ALL and LBL

On June 30, 2021, the U.S. Food and Drug Administration (FDA) approved asparaginase erwinia chrysanthemi (recombinant)-rywn as a component of a multi-agent chemotherapy regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients who are allergic to the E. coli-derived asparaginase products used most commonly for treatment.

Read the FDA announcement.

Read the Jazz Pharmaceuticals announcement.

Posted 7/1/2021

Upcoming Events

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual December 9, 2026 at 11:00 AM EST
2027 ACCC Leadership Summit

2027 ACCC Leadership Summit

In Person April 22, 2027 at 6:00 PM EDTWillard InterContinental Hotel, 1401 Pennsylvania Avenue Northwest, Washington, DC, USAWashington